2 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow Hypertension, Essential: new trials by email Literature Review of Hypertension, Essential trials Research Report on Hypertension, Essential
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed Nifedipine/Candesartan (BAY 98-7106), Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333) - Hypertension, Essential | Phase 1 | Completed | Bayer | 49 | 2011-04-01 | 2015-12-10 |
| Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions Nifedipine-candesartan FDC (BAY 98-7106), Nifedipine GITS (Adalat LA, BAYA1040), Candesartan (Atacand) - Hypertension, Essential | Phase 1 | Completed | Bayer | 49 | 2010-11-01 | 2015-12-10 |
Cardiovascular Diseases (2) · Hypertension (2) · Vascular Diseases (2)
Nifedipine (2) · candesartan (2) · candesartan cilexetil (2)
Bayer (2)
Germany (2)